The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Abstract
PURPOSE: Adjuvant chemotherapy improves disease-free survival (DFS) for patients with osteogenic sarcoma (OS). We reviewed our experience with OS to determine prognostic factors, the role of preoperative chemotherapy and subsequent histologic response, and the role of salvage chemotherapy after poor initial response. METHODS: From 1975 to 1984, we saw 279 patients with previously untreated OS without metastasis. All patients received intensive chemotherapy and underwent surgical resection of primary tumor. Chemotherapy included high-dose methotrexate; Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH); and bleomycin, cyclophosphamide, and dactinomycin (BCD). Selected patients also received cisplatin. RESULTS: DFS was not affected by use of preoperative chemotherapy versus immediate surgery, by use of limb-sparing surgery versus amputation, age, sex, or dose intensity of chemotherapy. DFS did correlate with serum lactate dehydrogenase (LDH), alkaline phosphatase, primary tumor site, race, and histologic response to preoperative chemotherapy. There was no difference in DFS for patients with a poor histologic response who did or did not receive cisplatin, although patients who did receive cisplatin had a longer time to relapse. The 5-year DFS was 76% for patients aged less than or equal to 21 years who had extremity primary tumor and were treated with the T10 protocol. CONCLUSIONS: Intensive chemotherapy can achieve DFS for a high proportion of patients with OS. Although it is a powerful predictor of DFS, histologic response to preoperative chemotherapy cannot be assessed at diagnosis. We have not shown an ability to salvage patients with an unfavorable response. We need to increase the proportion of patients with a favorable response, identify the patients who will have an unfavorable response, and develop novel treatments to salvage poor responders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Self-citationPrimary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6<2163::aid-cncr2820430602>3.0.co;2-s · Cited by 592
Self-citationWinkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Rosen, G., Murphy, M. L., Huvos, A. G., Gutierrez, M., & Marcove, R. C. (1976) · Cancer · doi:10.1002/1097-0142(197601)37:1<1::aid-cncr2820370102>3.0.co;2-3 · Cited by 353
Self-citationNeoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345
Edmonson, J. H., Green, S., Ivins, J. C., Gilchrist, G. S., Creagan, E. T., Dj, P., Smithson, W. A., Dahlin, D. C., & Taylor, W. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.152 · Cited by 105
Prognostic Variables in Osteosarcoma: A Multi-Institutional Study
Taylor, W. F., Ivins, J. C., Unni, K. K., Beabout, J. W., Golenzer, H. J., & Black, L. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.1.21 · Cited by 69
Mosende, C., Gutiérrez, M., Caparros, B., & Rosen, G. (1977) · Cancer · Cited by 66
Self-citationHeller, G., & Simonoff, J. S. (1992) · Biometrics · doi:10.2307/2532742 · Cited by 47
Self-citation
Cited by
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Self-citationCurrent and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 689
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657
Primary bone osteosarcoma in the pediatric age: State of the art
Longhi, A., Errani, C., De Paolis, M., Mercuri, M., & Bacci, G. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.05.005 · Cited by 631
Metadata
- Authors
- Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-01
- Volume
- 10
- Issue
- 1
- Pages
- 5-15
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142136189
- Cited by
- 678
- References
- 11
- FWCI
- 16.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. https://app.cochat.ai/papers/10.1200/jco.1992.10.1.5
- The paper
- Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992). Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1992.10.1.5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
